Table 1.
Clinical trials of targeting of HGF/c-MET in cancers.
| Inhibitor | Cancer Type | Characteristic | gov Identifier |
|---|---|---|---|
| Crizotinib (PF-02341066) |
NSCLC | Efficacy and safety test of PF-02341066 in cancer patients with alterations in ALK, MET, or ROS1. | NCT02034981 |
| NSCLC | To analyze PK and PD in patients with NSCLC, c-MET-dependent. | NCT00585195 | |
| NSCLC | Comparison of safety and anti-cancer efficacy of PF-02341066 versus pemetrexed or docetaxel in patients with NSCLC involving the ALK gene. | NCT00932893 | |
| Rilotumumab (AMG-102) |
CRC | To test the safety and efficacy of AMG-102 or ganitumab in combination with panitumumab in patients with metastatic wild-type KRAS CRC. | NCT00788957 |
| NSCLC | To evaluate AMG-102 and erlotinib in previously treated subjects with advanced NSCLC. | NCT01233687 | |
| Ficlatuzumab | PC | To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer. | NCT03316599 |
| SCCHN | To find the recommended dose of the combination of ficlatuzumab and cetuximab in patients with recurrent/metastatic SCCHN. | NCT02277197 | |
| YYB-101 | CRC | To evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of YYB-101 with irinotecan, patients who are metastatic or recurrent colorectal cancer patients. | NCT04368507 |
| AST | To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose of YYB-101 in advanced solid tumor patients who are refractory to standard therapy. | NCT02499224 |
Abbreviations: NSCLC, non-small cell lung cancer; CRC, colorectal carcinoma; PC, pancreatic cancer; SCCHN, squamous cell carcinoma of the head and neck; AST, advanced solid tumors.